Research

Hormonal

Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.

GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.

StrongSupportsmedium confidence
semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20%.
Roopesh Jain · Advances in Biomedical and Health Sciences · 2026

Why this rating

Based on the SELECT trial with a large sample size.

Source

Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies

Roopesh Jain · Advances in Biomedical and Health Sciences · 2026

DOI 10.4103/abhs.abhs_94_25

review · n=17604
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →